Application of Corilagin in preparing anti-tumor drugs
An anti-tumor drug, anti-tumor technology, applied in anti-tumor drugs, drug combinations, pharmaceutical formulations, etc., can solve problems such as unseen pharmacology and molecular mechanisms
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0021] Example 1 Inhibitory effect of Corilagin on liver cancer cells, ovarian cancer cells and normal cells in vitro
[0022] Experimental materials: cell lines, culture medium, drugs: human liver cancer cell Bel7402, SMMC7721, human ovarian cancer cell Hey, human normal liver cell Chang-liver and human normal ovarian epithelial cell NOE001 were purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences; Base RPMI 1640 was purchased from GIBCO Company, fetal bovine serum was purchased from Hyclone Company, penicillin and streptomycin were purchased from Shanghai Sangong Company; 3-(4,5-dimethylthiazole-2)-2,5-diphenyl Tetrazolium bromide (abbreviated as MTT), dimethyl sulfoxide (abbreviated as DMSO) and the like were purchased from Sigma or other domestic companies.
[0023] Experimental method: A group of corilagin at concentrations of 0, 6.25, 12.5, 25, 50, 100, and 200 μg / mL was applied to cells Bel7402, SMMC7721, Hey, Chang-liver, and NOE00172 h, and t...
Embodiment 2
[0025] Example 2 Currylatin's arresting effect on the cell cycle of ovarian cancer cell Hey
[0026] Hey cells were inoculated in 60mm culture dishes, and co-cultured with 17 μg / ml corilagin for 24h, 48h, and 72h (the method was the same as in Example 1), and a control was made. After being treated with 5 mg / ml PI containing 0.1% RNaseA in the dark for 10 min, it was detected by flow cytometry.
[0027]The results showed that from 24h to 72h, the G0 / G1 phase of the control group decreased from 48.88% to 39.29%, while that of the Corilagin group increased from 54.85% to 71.75% ( figure 2 ). It can be seen that Corilagin can arrest the cell cycle of ovarian cancer cell Hey in the G0 / G1 phase in a time-effect-dependent manner. See Table 1 for the cell cycle arrest effect of Corilagin on ovarian cancer cell Hey.
[0028] Table 1
[0029]
Embodiment 3
[0030] Example 3 Effect of Corilagin on TGF-β / PI3K / Akt / Snail Signaling Pathway in SKOV3ip Cells
[0031] Cell inoculation: Mix human ovarian cancer cell SKOV3ip in 10% FBS RPMI 1640 and inoculate in 60mm culture dish, the number of cells in each dish is 3.5×10 5 indivual. Drug addition: Add 32 μg / ml drug A and 17 μg / ml drug C to the cells in sequence.
[0032] After 12 hours: starvation: replace the culture medium with RPMI 1640 without FBS, and the drug concentration is the same as before.
[0033] After 36 hours: Add epidermal growth factor EGF (concentration: 20 μg / ml) to one of the two dishes of cells in each group, and act for 10 minutes to extract protein.
[0034] Western blot detection of pAkt and Akt: Bradford protein quantification method was used to make the total amount of protein per well 20 μg, and pAkt (p473) and Akt antibodies were used to detect (CST Company, rabbit anti-antibody, antibody concentration 1:1000).
[0035] The results show that Corilagin can ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com